|
Suprachoroidal Administration in Subjects With Metastases to the Choroid
RECRUITINGPhase 2Sponsored by Aura Biosciences
Actively Recruiting
PhasePhase 2
SponsorAura Biosciences
Started2024-12-16
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations10 sites
View on ClinicalTrials.gov →
NCT06643884
Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor. * Have at least one Metastases to the Choroid in the study eye Exclusion Criteria: * Active ocular infection or disease. * Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment. * Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
Conditions3
CancerEye CancerPrimary Cancer
Interventions1
Locations10 sites
Byers Eye Institute at Stanford University
Massachusetts Eye and Ear
Kellogg Eye Center
Ann Arbor, Michigan, 48105
Mayo Clinic
Find trials near these locations
Cancer trials in MiamiCancer trials in BostonCancer trials in ClevelandCancer trials in PhiladelphiaCancer trials in NashvilleCancer trials in SeattleAll trials in CaliforniaAll trials in FloridaAll trials in MassachusettsAll trials in MinnesotaAll trials in OhioAll trials in PennsylvaniaAll trials in TennesseeAll trials in TexasAll trials in Washington
Related trials
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorAura Biosciences
Started2024-12-16
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations10 sites
View on ClinicalTrials.gov →
NCT06643884